Ginsenoside Rh2(S) induces the differentiation and mineralization of osteoblastic MC3T3-E1 cells through activation of PKD and p38 MAPK pathways
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
As part of the search for biologically active anti-osteoporotic agents that enhance differentiation and mineralization of osteoblastic MC3T3-E1 cells, we identified the ginsenoside Rh2(S),which is an active component in ginseng. Rh2(S) stimulates osteoblastic differentiation and mineralization, as manifested by the up-regulation of differentiation markers (alkaline phosphatase and osteogenic genes) and Alizarin Red staining, respectively. Rh2(S) activates p38 mitogen-activated protein kinase (MAPK) in time- and concentration-dependent manners, and Rh2(S)-induced differentiation and mineralization of osteoblastic cells were totally inhibited in the presence of the p38 MAPK inhibitor,SB203580. In addition, pretreatment with Go6976, a protein kinase D (PKD) inhibitor, significantly reversed the Rh2(S)-induced p38 MAPK activation, indicating that PKD might be an upstream kinase for p38 MAPK in MC3T3-E1 cells. Taken together, these results suggest that Rh2(S) induces the differentiation and mineralization of MC3T3-E1 cells through activation of PKD/p38 MAPK signaling pathways, and these findings provide a molecular basis for the osteogenic effect of Rh2(S). [BMB reports 2011; 44(10): 659-664]
Abstract
As part of the search for biologically active anti-osteoporotic agents that enhance differentiation and mineralization of osteoblastic MC3T3-E1 cells, we identified the ginsenoside Rh2(S),which is an active component in ginseng. Rh2(S) stimulates osteoblastic differentiation and mineralization, as manifested by the up-regulation of differentiation markers (alkaline phosphatase and osteogenic genes) and Alizarin Red staining, respectively. Rh2(S) activates p38 mitogen-activated protein kinase (MAPK) in time- and concentration-dependent manners, and Rh2(S)-induced differentiation and mineralization of osteoblastic cells were totally inhibited in the presence of the p38 MAPK inhibitor,SB203580. In addition, pretreatment with Go6976, a protein kinase D (PKD) inhibitor, significantly reversed the Rh2(S)-induced p38 MAPK activation, indicating that PKD might be an upstream kinase for p38 MAPK in MC3T3-E1 cells. Taken together, these results suggest that Rh2(S) induces the differentiation and mineralization of MC3T3-E1 cells through activation of PKD/p38 MAPK signaling pathways, and these findings provide a molecular basis for the osteogenic effect of Rh2(S). [BMB reports 2011; 44(10): 659-664]
참고문헌 (20)
- Miao, D, "Osteoblast- derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34", J. Clin. Invest, 15, pp.2402~2411 (2005)
- Genant, H. K, "Estrogens in the prevention of osteoporosis in postmenopausal women. Am. J. Obstet", Gynecol, 191, pp.1842~1846 (1989)
- Reid,I.R, "Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety", Expert Opin. Drug Saf, 1, pp.93~107 (2002)
- Turner,C.H, "Homeostatic control of bone structure: an application of feedback theory", Bone, 12, pp.203~217 (1991)
- Shin, H. Y, "The effect of Panax ginseng on forced immobility time & immune function in mice", Indian J. Med. Res, 124, pp.99~206 (2006)
- Wang, W, "In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng", Cancer Chemother. Pharmacol, 59, pp.589~601 (2007)
- Polan, M. L, "Estrogen bioassay of ginseng extract and ArginMax, a nutritional supplement for the enhancement of female sexual function", J. Womens Health, 13, pp.427~430 (2004)
- Hwang, J. T, "Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 364, pp.1002~1008 (2007), ELSEVIER
- Kim, H. R, "Effect of ginseng mixture on osteoporosis in ovariectomized rats", Immunopharmacol. Immunotoxicol, 30, pp.333~345 (2008), Infoma health
- Liu, J, "20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastogenesis inhibitor without any cytotoxicity", Bioorg. Med. Chem. Lett, 19, pp.3320~3323 (2009)
- Attele, A. S, "Ginseng pharmacology: multiple constituents and multiple actions", Biochem. Pharmacol, 58, pp.1685~1693 (1999)
- Nakata, H, "Inhibitory effects of ginsenoside Rh-2 on tumor growth in nude mice bearing human ovarian cancer cells", JPN J. Cancer Res, 89, pp.733~740 (1998)
- Popovich, D. G, "Mechanistic studies on protopanaxadiol, Rh2, and ginseng (Panax quinquefolius) extract induced cytotoxicity in intestinal Caco-2 cells", J. Biochem. Mol. Toxicol, 18, pp.143~149 (2004)
- Mund, G, "Stimulation of bone formation in vitro and in rodents by statins", Science, 1286, pp.1946~1949 (1999)
- Jeong, H. M, "Saponins from the roots of Platycodon grandiflorum stimulate osteoblast differentiation via p38 MAPK- and ERK-dependent RUNX2 activation", FOOD AND CHEMICAL TOXICOLOGY, 48(12), pp.3362~3368 (2010), PERGAMON-ELSEVIER SCIENCE LTD
- Lin, F. H, "Role of mitogen-activated protein kinase in osteoblast", J. Orthop. Res, 29, pp.204~210 (2011)
- Alessi, D, "PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo", J. Biol. Chem, 270, pp.27489~27494 (1995)
- Lemonnier, J, "Protein kinase C-independent activation of protein kinase D is involved in BMP-2-induced activation of stress mitogen-activated protein kinase JNK and p38 and osteoblastic cell differentiation", J. Biol. Chem, 279, pp.259~264 (2004)
- Yang, R. S, "Regulation by ultrasound treatment on the integrin expression and differentiation of osteoblasts", Bone, 36, pp.276~283 (2005)
- Ducy, P, "The osteoblast: A sophisticated fibroblast under central surveillance", Science, 289, pp.1501~1504 (2000)